Search Results

Neuroendocrine cancer (including neuroendocrine tumors/NET or neuroendocrine carcinoma/NEC) can feel isolating. Because the disease is uncommon and often misunderstood, many patients and caregivers spend months or years searching for clear information, experienced providers, and people who truly understand what they are facing. That is why in-person education and connection matters. The 2026 NET Cancer Day Symposium will bring the neuroendocrine cancer community together in Las Vegas, Nevada, on Sunday, November 8th, to focus on education, connection, and awareness. This is an opportunity for patients, caregivers, and advocates to interact with healthcare professionals in an intimate forum. You’ll be provided with the rare opportunity to hear directly from clinicians and specialists who understand neuroendocrine cancer and can help patients and caregivers build their knowledge, better understand the disease, learn about current therapies, and gain insight into questions they may want to discuss with their own care teams. This can help you feel more prepared and empowered to tackle your care and navigate complex decisions. The goal is not to replace conversations with your medical team. Instead, educational events can help you become a well-informed partner in those conversations. Education does not only come from the stage. It also comes from conversations in the room. The symposium is intended to create space for connection among patients, caregivers, clinicians, advocates, and supporters. Living with neuroendocrine cancer can bring uncertainty, stress, and emotional challenges. In-person gatherings can help patients and caregivers feel less alone and more connected to a community that understands the realities of neuroendocrine cancer. Hearing from others who are living with neuroendocrine cancer, caring for a loved one, or working to advance the field can offer encouragement, perspective, and a renewed sense of solidarity. “I have been part of the NET community for more than a decade, and some of my most meaningful experiences have come from sitting with the NCF team, exchanging ideas and shaping topics for meetings throughout the years—not only for NET Cancer Day. We do this because we genuinely love the work and care deeply about creating valuable experiences for the NET community. It is especially meaningful to have such an active role in planning and hosting the 2026 NET Cancer Day Symposium, and I am truly looking forward to welcoming everyone for a productive, engaging, and exciting meeting.” - Taymeyah Al-Toubah, Interim NCF Program Director RAISE AWARENESS TOGETHER NET Cancer Day is a global opportunity to increase awareness of neuroendocrine cancer. The 2026 NET Cancer Day Symposium will be part of that broader effort by bringing people together to learn, connect, and help expand understanding of this complex and often misdiagnosed disease. When patients, caregivers, advocates, clinicians, and supporters gather in person, they help enhance neuroendocrine cancer awareness within your community. JOIN US IN LAS VEGAS The 2026 NET Cancer Day Symposium will take place in Las Vegas, Nevada, from 8:30 AM to 3:00 PM, on Sunday, November 8th, at the JW Marriott Las Vegas Resort & Spa, 221 N Rampart Blvd Las Vegas, NV 89145. Whether you are newly diagnosed, have been living with neuroendocrine cancer for years, are caring for a loved one, or want to better understand this disease, the symposium is an opportunity to learn, connect, and take the next step with support. Thanks to the generosity of sponsors, we invite you to join us at no cost. Breakfast, lunch and beverages will be provided. Register for this in-person event: NCF.net/events/ncd2026 THANKS TO OUR SPONSORS

Taymeyah Al-Toubah, MPH, CCRP The Neuroendocrine Cancer Foundation ("NCF") is grateful to welcome Taymeyah Al-Toubah, MPH, CCRP, in a special support role as the Interim Program Director during the remainder of 2026. Taymeyah will support NCF’s programs and educational efforts from July 1 through December 31, 2026, helping ensure continuity for the patients, caregivers, clinicians, and community members who rely on NCF for trusted education, resources, and connection. This temporary support comes as Lisa Yen, NP, NBC-HWC, NCF’s Director of Programs & Outreach, takes time following the passing of her beloved husband, Tom Bajoras. Taymeyah brings more than a decade of experience in academic medicine, clinical research, oncology, and neuroendocrine tumor research. She holds dual bachelor’s degrees in Biomedical Sciences and Psychology and a Master of Public Health in Epidemiology. Her interest in neuroendocrine tumors began during her MPH thesis, which became one of her first NET publications. From 2018 to 2023, Taymeyah served as the primary neuroendocrine tumor (NET) coordinator at Moffitt Cancer Center, managing clinical trials, leading the GI team, and supporting retrospective and non-interventional research. She later served as Senior Project Manager of the NET program, overseeing protocol development, database creation, manuscript writing, and the curation of a master database of more than 10,000 NET patients. Taymeyah has published more than 45 manuscripts and has presented at both Europeon Neuroendocrine Tumor Society (ENETS) and the North American Neuroendocrine Tumor Soceity (NANETS). She serves on the Board of Directors of NANETS and co-founder and medical advisory committee of FLaNET Carcinoid Community, and she continues to mentor students pursuing neuroendocrine tumor research. In 2025, she began medical school in Italy, continuing her path toward becoming a physician-scientist dedicated to advancing care for neuroendocrine cancer patients. We are thankful to Taymeyah for stepping in during this meaningful time and grateful to our staff, Board, volunteers, medical advisors, and community partners for continuing to support NCF’s mission. As always, NCF remains committed to providing trusted education, support, and resources for people impacted by neuroendocrine cancer. If you have any questions, email the NCF team at info@NCF.net. THANKS TO OUR SPONSORS

Team Craig chose the Neuroendocrine Cancer Foundation (NCF) to support its work on behalf of patients and families affected by neuroendocrine cancer. Team Craig is named in honor of Craig Adams, who lost his battle with a form of neuroendocrine cancer in 2015. His sons, Ben and John Adams, promised to honor his legacy and give back to the community that helped give their family eight extra years with him. What began as a tribute to their father has grown into a powerful tradition: each year, a lacrosse team made up of friends and teammates from across the country competes in the Vail Lacrosse Shootout, united by Craig’s legacy and a shared passion for the game. Team Craig has quickly become one of the top competitors in the tournament, finishing third in 2024 and winning the tournament championship in 2025. In 2026, the team returned to compete again with a renewed mission to raise awareness and funds for families affected by neuroendocrine cancer. This year, Team Craig took that mission one step further by dedicating its efforts to supporting NCF’s work to expand awareness, education, and patient resources for those impacted by this complex and uncommon disease. The effort included a casual community gathering at Ratio Beerworks - OVERLAND in Denver, where supporters came together for live music, refreshments, conversation, and community in support of NCF. Neuroendocrine cancer can be difficult to diagnose and treat, and many patients experience years of misdiagnosis or undiagnosed symptoms. NCF works to change that by providing education and resources for patients and caregivers, increasing awareness and understanding of neuroendocrine cancers, connecting patients to experts and information about treatment options and clinical trials, and supporting a community for people navigating diagnosis and care. As Heather Davis, NCF’s Director of Community Engagement, reflected, navigating a difficult cancer can feel a lot like the unpredictable path of a loose ground ball in lacrosse. You never know exactly which way it will bounce, and the next challenge can come quickly. For many people living with neuroendocrine cancer, that uncertainty is part of daily life. There is often a constant need to adapt, make decisions, overcome obstacles, and prepare for what comes next. In lacrosse, one of the most important skills is cradling the ball: keeping it secure in the pocket of the stick while running, dodging defenders, preparing to pass, or taking a shot. That image feels especially meaningful for the neuroendocrine cancer community. Living with an uncommon cancer requires strategy, skill, focus, and agility. It requires a team that can help protect, guide, and support patients and families as they move through each stage of care. That is why NCF is so grateful to Team Craig, the Adams family, Chase Konkel, and everyone who helped bring this effort to life. Their generosity and commitment are helping NCF “cradle” the neuroendocrine cancer community by supporting those living with this uncommon cancer and helping connect more people to the resources and expertise they need. Although Team Craig did not take home the championship this year, their presence on the field represented something far greater than a final score. They played with purpose, honoring Craig’s memory and continuing a legacy rooted in teamwork, resilience, and care for others. NCF believes it takes a strong team to face cancer and to live well despite it. Team Craig is helping make that possible so that no one has to face neuroendocrine cancer alone. A special shoutout to Bodango for bringing the music and positive energy to the event and helping make the gathering even more memorable. We extend our heartfelt thanks to Ben and John Adams, Chase Konkel, the Adams family, donors, supporters, and Team Craig Lacrosse. Your commitment to this community is deeply meaningful, and your support will help NCF continue providing education, connection, and hope to patients and families affected by neuroendocrine cancer.

<< Go back to the Podcast page EPISODE 54 - NEN Treatments: Focus on Cabozantinib Download a Transcript of this Episode >>> ABOUT THIS EPISODE Since its FDA approval on March 26, 2025, cabozantinib has emerged as the newest treatment option for NET patients—adding another valuable tool to the treatment toolbox. It’s become a hot topic in support groups and forums, with many patients wondering what to expect. In this episode, Fox Chase Cancer Center medical oncologist Dr. Namrata (“Neena”) Vijayvergia answers the most frequently asked questions about cabozantinib. She explains how it works, how it differs from other therapies, what patients should know about dosing and side effects, and shares insights on a new clinical trial exploring the next generation of cabozantinib. TOP TEN QUESTIONS What is cabozantinib? Is it considered chemotherapy? How does cabozantinib work? What do we mean by “targeted therapies”? Who is cabozantinib typically recommended for? When in someone’s NET journey do you consider starting it? Why might a patient take cabozantinib instead of other treatment options? Is this a “last resort” treatment option? Does it limit future choices or “burn any bridges”? What are the most common side effects? Will I look like a cancer patient? Will my hair fall out? How might I feel while taking it—can most people keep working and doing their usual activities? Do common side effects tend to develop or get worse over time, or pretty much stay the same? What should patients watch out for or monitor while taking this medication? What should patients know about dosing? Is there a preferred starting dose or an “optimal” dose? If I tolerate a lower dose, should I go to a higher dose? What happens if cabozantinib doesn’t work for me? What other treatments might be available? I’ve heard about a drug called “Zanza,” the STELLAR-311 trial. What is it, and how does it fit into the current treatment landscape? What practical tips or “tricks of the trade” do you share with patients who may start this medication? Bonus: What’s on the horizon in NET research or treatment that you’re most excited about? MEET DR. NAMRATA (NEENA) VIJAYVERGIA Namrata (Neena) Vijayvergia, MD, FACP Gastrointestinal Medical Oncologist Fox Chase Cancer Center Philadelphia, PA Namrata (Neena) Vijayvergia, MD, FACP, is a GI medical oncologist, clinical trialist, and physician leader known for bringing science, collaboration, and heart to the care of patients with gastrointestinal and neuroendocrine cancers. She is Section Chief of Gastrointestinal Oncology at Fox Chase Cancer Center and an Associate Professor, where she leads a broad research program—from early-phase therapeutics to biomarker-driven strategies and patient-centered outcomes—supported by NIH, NCCN, industry partners, and foundations. Neena is a frequent speaker at national and international meetings, including ASCO, NANETS, ESMO, and SNMMI, and was recently honored with the 2025 Distinguished Clinical Award from NANETS. She helps set national standards through service on ASCO, NCCN, ENETS, NCI, and NANETS committees and guideline panels, chairs the NANETS Scientific Review Committee, and leads cooperative group efforts within ECOG-ACRIN. A dedicated mentor and advocate, she supports trainees and junior faculty through formal mentoring programs, advises patient advocacy organizations, and engages in community-focused efforts to make cancer care more inclusive and equitable. Recognized in the ASCO Leadership Development Program and as a “40 Under 40 in Cancer,” she brings a strategic yet people-first approach to clinical trial development—always driven by the belief that teamwork, curiosity, and compassion can move the field forward for patients and the teams who care for them. RESOURCES Learn More About Cabozantinib and The Cabinet Trial READ Read March 26, 2025 blogpost: Positive Results of the CABINET Trial Show Cabozantinib as a New, Effective Treatment in Advanced Neuroendocrine Tumors "Gastroenteropancreatic Neuroendocrine Tumors" Review article by Vijayvergia et al WATCH https://www.youtube.com/watch?v=balUaCFLceI Dr. Aman Chauhan Provides an Update on Cabozantinib https://www.youtube.com/watch?v=EK0wHgui9d4 Lisa Yen Provides Tips & Tricks for Cabozantinib LISTEN Episode 50: Spotlight on Pharmacists CLINICAL TRIAL STELLAR-311: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Cancers DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

The Neuroendocrine Cancer Foundation Podcast (previously known as the LACNETS Podcast) is a monthly series where we interview neuroendocrine tumor (NET) experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand NET. The Neuroendocrine Cancer Foundation Podcast is also available on Apple Music, Spotify, Google Podcasts, and Amazon Music. Be sure to subscribe to our podcast to receive notifications when new episodes are released! 2026 2025 2024 2023 2022 2021 2026 2026 LISTEN LISTEN 2025 2025 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2024 2024 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2023 2023 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2022 2022 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2021 2021 LISTEN LISTEN LISTEN LISTEN LISTEN

Connect with the Neuroendocrine Cancer Foundation for vital resources and a supportive community tailored for NET patients and their caregivers. Watch Podcast Blog Resources by Topic LATEST FROM NCF Registration Now Open - "Living With Neuroendocrine Cancer: The Caregiver/Co-Survivor Perspective" New Podcast - "Spotlight on Surgical Oncology" with Dr. Concors New - "Luncheon With The Experts" with Dr. Del Rivero Blog Pos t - "Continuing A 60-Year Legacy" "2025 Highlights in Neuroendocrine Cancer" New Blogpost - "The Email That Changed Everything" - Dusty Hurley New Educational Event - "The Latest on Immunotherapy for Neuroendocrine Cancer" with Dr. Aman Chauhan New Podcast Episode - "Spotlight on Pharmacists" with Amanda Cass, PharmD, BCPS, BCOP Watch "2025 Updates in NET" with Dr. Aman Chauhan Watch "The Latest in High-Grade Neuroendocrine Carcinoma (NEC)" with Dr. Aman Chauhan Watch "The Latest Advances in Neuroendocrine Cancer: An Update with Dr. Udhayvir Grewal" Watch "Bridging Inequities in Neuroendocrine Cancer Care: A Conversation" with Dr. Udhayvir Grewal SIGN UP FOR EMAIL Stay up-to-date with neuroendocrine cancer news, educational information, monthly newsletters and ways to connect with other neuroendocrine cancer patients and caregivers. Make a Difference Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for NET patients and caregivers. DONATE UPCOMING NCF EVENTS "Living With Neuroendocrine Cancer: The Caregiver/Co-Survivor Perspective July 30, 2026 Virtual Webinar Watch NET Cancer Day Symposium in Las Vegas, NV Nov 8, 2026 Virtual Webinar Register Visit our events page for more information >>> MAKE A DIFFERENCE Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for neuroendocrine cancer patients and caregivers. Donate LATEST ON CLINICAL TRIALS Clinical Trials News Play Video Play Video 06:31 Update on Cabozantinib Neuroendocrine Cancer Foundation Interview with Dr. Aman Chauhan • 2025 Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Dr. Chauhan explains why Cabozantinib—a VEGF TKI targeted therapy—is transforming care for patients who often have limited treatment options, especially those with somatostatin receptor–negative lung NETs who may not qualify for somatostatin analogs (SSA) or PRRT. He also discusses promising results in higher-grade (G2–G3) well-differentiated NETs, an area with few effective treatment choices. ✔ What the CABINET trial revealed ✔ Why Cabozantinib is effective across multiple NET types ✔ How lung and thymic NET patients (thoracic NETs) benefited—~80% of the thoracic subgroup were lung NETs ✔ How this approval is changing clinical practice ✔ Introduction to Zanzalintinib (Zanza) — a next-generation VEGF TKI now entering phase 3 trials ✔ How to find NET clinical trials near you on ClinicalTrials.gov If you’re a patient, caregiver, or healthcare professional looking for new NET treatment options, this update provides essential insights into where the field is headed and how future drugs are being developed. 🔗 Search for NET clinical trials: https://www.ncf.net/clinical-trials Play Video Play Video 04:02 The Latest Advances in Neuroendocrine Cancer: An Update with Dr. Udhayvir Grewal • 2025 In this conversation, Dr. Udhayvir Grewal from the Winship Cancer Institute at Emory shares the newest developments in neuroendocrine cancer (NET/NEC) research, treatment, and clinical trials — offering clarity, progress updates, and hope for patients and caregivers in the NET community. 🔬 Key Highlights: - Alpha PRRT (Alpha Radioligand Therapy): New investigational treatments including Lead-212 Dotamtate, Lead-212 VMT-Alpha-NET, and Actinium-225 Dotatate (ACTION-1) are showing promising early results and may change the treatment landscape for NET patients. - New FDA-Approved Therapy for Pheochromocytoma & Paraganglioma: Belzutifan is now available for a subset of patients, supported by durable response data from the LITESPARK study. - Advances in High-Grade Neuroendocrine Carcinoma: Encouraging results are emerging from trials targeting DLL3, including obrixtamig, radioligand therapies, ADCs, and tri-specific drugs currently in development. 📍 Next Steps & Resources To explore active clinical trials and educational resources, visit: 🔗 NCF.net #NeuroendocrineCancer #NETCancer #NeuroendocrineTumor #CancerResearch #PRRT #ClinicalTrials #PatientEducation #NCF #NETUpdates #AlphaPRRT #DLL3 Play Video Play Video 06:26 The Latest in High-Grade Neuroendocrine Carcinoma (NEC): A Conversation with Dr. Chauhan • 2025 In this important update, Dr. Aman Chauhan shares the newest and most promising developments in treatment and research for high-grade neuroendocrine carcinoma (NEC) — a rare and aggressive form of neuroendocrine cancer. For decades, treatment options for NEC have been limited and outcomes have remained largely unchanged. Today, that reality is beginning to shift — and this conversation highlights the progress bringing renewed hope to patients and families. Highlights in This Discussion: - DLL3-targeted immunotherapy, including T-cell engagers such as tarlatamab and emerging therapies like Obrixtamig - Ongoing progress in clinical trials for high-grade NEC - Early success with radiopharmaceutical approaches targeting DLL3 - Exploration of oncolytic viruses, including the Seneca Valley Virus combined with ipilimumab (ipi) and nivolumab (nivo) - Advances in next-generation immunotherapy, including CAR-T and checkpoint combinations 📍 Want to Learn More? To explore active or upcoming clinical trials for NEC, visit the Neuroendocrine Cancer Foundation’s Clinical Trials Guide at NCF.net/clinical-trials #NeuroendocrineCancer #NEC #HighGradeNEC #ClinicalTrials #Immunotherapy #DLL3 #PatientEducation #NETCancer #NeuroendocrineTumor #CancerResearch #NCF Play Video Play Video 06:20 Dr. Jennifer Chan Shares 2025 Highlights & Future Directions in NET Research at the 2025 INCA Summit In this exclusive 2025 INCA Summit interview, Lisa Yen from the Neuroendocrine Cancer Foundation speaks with Dr. Jennifer Chan, President of NANETS and medical oncologist at Dana-Farber Cancer Institute, about the latest advances and future directions in neuroendocrine cancer research and treatment. Dr. Chan reflects on her 20-year journey in the field and highlights a pivotal year for neuroendocrine cancer care — including the FDA and EMA approvals of cabozantinib for both pancreatic and extrapancreatic NETs, and belzutifan for advanced pheochromocytomas and paragangliomas. She discusses how these breakthroughs are expanding treatment options and offering renewed hope to patients worldwide. Looking ahead, Dr. Chan shares her excitement about ongoing and upcoming clinical trials, including the COMPETE trial (PRRT vs. everolimus) and studies involving alpha-emitting PRRT agents, which may further transform clinical practice. 🎥 Highlights: Global collaboration through the International Neuroendocrine Cancer Alliance (INCA) Major new treatment approvals in 2025 (cabozantinib, belzutifan) Promising data from recent and emerging clinical trials (COMPETE, PRRT advances) A look toward the next wave of neuroendocrine cancer research 📍 Recorded live at the 2025 INCA Summit in Sofia, Bulgaria 👩⚕️ Guest: Dr. Jennifer Chan, President of NANETS 🎙️ Host: Lisa Yen, Neuroendocrine Cancer Foundation #NeuroendocrineCancer #INCA2025 #NANETS #Cabozantinib #Belzutifan #DanaFarber #OncologyResearch #PatientAdvocacy Play Video Play Video 05:29 Dr. Jennifer Chan & Dr. Del Rivero Discuss Advancing NET Research at the 2025 INCA Summit In this insightful conversation from the 2025 INCA Summit in Sofia, Bulgaria, leading neuroendocrine cancer experts Dr. Jennifer Chan (Dana-Farber Cancer Institute, USA) and Dr. Jaydira Del Rivero (National Cancer Institute, NIH) discuss the future of neuroendocrine tumor (NET) research, emphasizing the importance of clinical trials, patient engagement, and international collaboration. Dr. Del Rivero highlights the mission of INCA’s research committee—to align scientific priorities with patient needs, ensure greater patient participation in research, and develop better models and biomarkers for understanding and treating NETs. She explains the range of clinical research, from translational and molecular studies to natural history, prevention, and treatment trials, and how each contributes to improving diagnosis, therapy, and quality of life for patients. Dr. Chan underscores the vital role of patients as partners in research, helping shape meaningful endpoints and driving practice-changing discoveries like the CABINET trial, which recently led to new treatment approvals for neuroendocrine cancers. 🎥 Highlights: The mission of the INCA Research Committee Translational research and model development for NETs The value of biomarkers and molecular insights Understanding natural history studies and their role in cancer discovery Empowering patients as research partners Reflections on the impact of the CABINET study 📍 Recorded live at the 2025 International Neuroendocrine Cancer Alliance (INCA) Summit, Sofia, Bulgaria 👩⚕️ Speakers: Dr. Jennifer Chan & Dr. Jaydira Del Rivero #NeuroendocrineCancer #INCA2025 #ClinicalTrials #CancerResearch #PatientAdvocacy #DanaFarber #NIH #NANETS #CABINETTrial #OncologyResearch Play Video Play Video 05:30 Dr. Halfdanarson on ITM’s COMPETE Trial • 2025 ENETS • Neuroendocrine Cancer Foundation NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials. Play Video Play Video 05:27 Dr. Jennifer Chan Discusses Results of CABINET Trial (Cabozantinib) as Effective Treatment at ESMO24 Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n Play Video Play Video 04:44 Dr. Aman Chauhan About the Most Exciting Progress in the Neuroendocrine Cancer Field @ NANETS Miami In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami NETTER-2 Trial Supports Lutathera® as 1st Line Treatment >>> Dr. Jennifer Chan Announces the CABINET Trial Data on Cabozantinib >>> Clinical Trials Guide WATCH 550+ Videos on Various Topics 2025 NET Cancer Day Symposium LISTEN Hear Experts Answer Top 10 Questions on Each Topic "Against the Tide: The Mary Donlevy Story" TAKE ACTION Learn How You Can Share Your Story RECENT EDUCATIONAL EVENTS FOR PATIENTS Play Video Play Video 01:34:59 Just Diagnosed With Neuroendocrine Cancer? What to Know and Understand • 2026 NCF Event • Apr 23, 26 ABOUT Being newly diagnosed with neuroendocrine cancer (NETs) can feel overwhelming. Many patients find themselves asking, “What exactly is neuroendocrine cancer, and how is it different from other cancers?” This webinar is designed to bring clarity, reassurance, and guidance during one of the most confusing stages of the NET journey. Join Dr. Osama MoSalem, medical oncologist at St. Luke’s in Kansas City, for a clear and compassionate overview of what every newly diagnosed NET patient should know. Dr. MoSalem explains what neuroendocrine cancer is, why it behaves differently from more common cancers, and how its unique features influence diagnosis and treatment. This session walks you through the most important early concepts, including: - Grade and stage: what they mean and why they matter - Key tests and scans used at diagnosis - Treatment pathways, including when to consider surgery, medications, targeted therapies, radioligand therapy, or clinical trials - Essential questions to ask your care team - Practical first steps to help you feel more prepared and empowered Whether you’re newly diagnosed, supporting a loved one, or simply trying to better understand this disease, this webinar provides a solid foundation to help you make informed decisions with greater clarity and confidence. Visit the event page at https://www.ncf.net/events/apr2026 Play Video Play Video 01:33:06 Novel Targeted Therapies in Neuroendocrine Cancers • 2026 NCF Event • Mar 9, 2026 Some Topics Covered: Neuroendocrine, NET, NEC, High-grade Clinical trials, PRRT, RLT, Antibody Drug Conjugate (ADC), DLL3 ABOUT Learn from a discussion of targeted therapies in neuroendocrine cancer, one of the fastest-growing areas of NET treatment. Unlike traditional chemotherapy, targeted therapies focus on specific pathways or features of cancer cells. Understanding how these treatments work can help patients feel more confident and informed when discussing options with their care team. In this session, Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center, explores novel, innovative targeted treatments used or being studied in NETs, such as DLL3 and antibody–drug conjugates (ADCs). Dr. Thummalapalli will explain what these therapies are, how they work, and why they are becoming increasingly important in NET care. Whether you’re newly diagnosed or considering later-line treatments, this webinar will help you better understand the evolving landscape of targeted therapy and what it may mean for your care. Visit the event page at https://www.ncf.net/events/mar2026 Play Video Play Video 01:29:26 The Latest in Neuroendocrine Cancer Clinical Trials • 2026 NCF Event • Feb 20, 2026 Topics Covered: Neuroendocrine, NET, clinical trials, PRRT, RLT, neoadjuvant trials, adjuvant trials, metastatic NET, symptom control ABOUT Join us for an overview of the latest clinical trials in neuroendocrine cancer with Dr. Heloisa Soares, a medical oncologist and physician-scientist at the Huntsman Cancer Institute (HCI) in Salt Lake City. Dr. Soares will walk through key neuroendocrine cancer clinical trials including what they are studying, what makes them exciting, and how they may shape future treatment options. She will also explain why clinical trials matter, how they benefit patients, and what to consider when exploring whether a trial might be right for you. Whether you’re a patient, caregiver, or simply trying to stay informed, this webinar will provide clear, practical insights to help you better understand emerging research and what it means for the neuroendocrine cancer community. The presentation focuses on current NET clinical trials. For information on NEC clinical trials, go to our high grade resources page: https://www.ncf.net/high-grade-nen-resources. Visit the event page at https://www.ncf.net/events/feb2026 Play Video Play Video 01:31:30 The Latest on Immunotherapy for Neuroendocrine Cancer • 2025 NCF Event • Dec 11, 2025 Immunotherapy is an exciting and rapidly advancing area in the treatment of neuroendocrine cancer. Join Dr. Aman Chauhan, Medical Oncologist at the University of Miami Sylvester Cancer Center, as he discusses the latest developments in immunotherapy for neuroendocrine cancer. This webinar will cover current standard-of-care treatments as well as cutting-edge clinical trials involving DLL3-targeted therapies, oncolytic viruses, CAR T-cell therapy, and combination approaches. Whether you’re newly diagnosed or exploring new treatment options, this session will help you better understand the evolving landscape of immunotherapy in neuroendocrine cancer. Aman Chauhan, MD Medical Oncologist University of Miami Sylvester Cancer Center Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer Institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is the national principal investigator on several investigator-initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. Visit https://www.ncf.net/events/dec2025 for more information. Play Video Play Video 01:27:39 Understanding Alpha & The Evolving PRRT Landscape • Dr. Grewal • 2025 NCF Event • September 22, 2025 The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. For more information, visit https://www.ncf.net/events/sep2025. Play Video Play Video 01:25:23 Nutrition & Diet Considerations for NETs • 2025 NCF Event • August 26, 2025 Nutrition can play a key role in living well with neuroendocrine cancer (neuroendocrine tumors or NETs). Join NET dietitian Meghan Laszlo for an informative session on nutrition and diet considerations for people living with neuroendocrine cancer. She will cover key topics including the use of pancreatic enzymes, managing hyperglycemia, navigating special diets, and understanding supplements. Whether you're newly diagnosed or further along in your journey, this webinar offers practical guidance to help you make informed nutrition choices that support your health and quality of life. For more information, visit ncf.net. Play Video Play Video 01:16:25 Living with NET: The Patient Perspective • 2025 NCF Event • July 10, 2025 Patients share their experiences on topics, including decision-making, coping strategies, lessons learned, challenges, and navigating relationships while living with neuroendocrine cancer. Hear about their personal journeys—filled with resilience, realities, and hope, that offer powerful insight into what it's like living with neuroendocrine cancer. Visit NCF.net/July2025 for more information. Play Video Play Video 01:33:27 "Evolving Management of Carcinoid Heart Disease" • Prashanth Venkatesh, MD, FACC • April 29, 2025 Learn from Cardiologist and Congenital Heart Disease Specialist, Dr. Prashanth Venkatesh from Cedars-Sinai Smidt Heart Institute in a virtual educational event on carcinoid heart disease. Dr. Venkatesh demystifies the topic and shares the latest developments in its diagnosis and treatment, including a novel minimally invasive approach to replace heart valves damaged by carcinoid heart disease. For more information and resources, visit NCF.net. LATEST PODCAST EPISODES LISTEN LISTEN LISTEN LISTEN RESOURCES & INFORMATION FOR YOU Meetings Register for the upcoming educational webinars and programs Support Groups Learn about the NET patient and caregiver support groups Podcast A podcast series where neuroendocrine cancer experts answer the top 10 FAQs on various topics Resources Check our resource navigation guide which covers various topics from treatment options to wellness NETCONNECT A peer support system that connects newly-diagnosed patients with mentors Newly Diagnosed Newly-diagnosed NET patients can begin exploring here for resources and support NET VITALS A tool for patients and healthcare professionals to share vital information about a patient’s neuroendocrine cancer Clinical Trials Explore open clinical trials here Blog Read about various NET topics, inspiring survival stories, and tips to live fully and richly with cancer Patient & Caregiver Stories Find inspiration and hope from NET patient and caregiver stories Spanish Resources Explore Spanish-language resources for NET patients and caregivers Health Coaching Learn how you can receive one-on-one coaching sessions available to NET patients and caregivers ABOUT THE NEUROENDOCRINE CANCER FOUNDATION Why Our Work Matters The Neuroendocrine Cancer Foundation (NCF) exists to ensure no one faces neuroendocrine cancer alone. We support patients, caregivers, and clinicians through education, connection, and compassionate resources. Educate Educational Events Luncheon With The Experts w/Live Q&A In-Person Patient & Caregiver Events Online Video Library (YouTube & Web) Resource Library on 25 Topics Podcast Spanish Resources Support Support Line Resources for Newly Diagnosed Support Groups Health & Wellness Retreat Wellness Coaching Connect NETCONNECT Peer-to-Peer Program NET VITALS NET INTRO Inform Clinical Trials Guide Amplify Patient Voice Neuroendocrine cancer (also known as NET, neuroendocrine tumor, neuroendocrine neoplasm, carcinoid, or neuroendocrine carcinoma) is a rare/uncommon and complex disease. 8 in 100,000 people in the U.S. are diagnosed each year Symptoms vary widely and are often misunderstood Diagnosis can take several years Many patients do not meet someone else living with neuroendocrine cancer until they find NCF Patients often struggle to find specialists, up-to-date treatment guidance, and emotional support. NCF fills those gaps by offering what patients need most: credible education, expert access, and a community that understands. NCF provides these life-changing resources — ensuring patients and families receive guidance when it matters most. I was officially diagnosed on June 29, 2022. I didn’t even know NETs existed. And today...less than a month later, I’ve learned so much thanks to the incredible resources that exist as a result of the beautiful NETs community. The resources available, especially the videos from the (Neuroendocrine Cancer Foundation) and the NET VITALS document, are so life-giving and helpful for the newly diagnosed. The Neuroendocrine Cancer Foundation contributes so much useful information to the NET community. — NET Patient Leave A Review